Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
+0.31 (0.63%)
Pre-market: 49.98 +0.25 (0.50%)
Feb 21, 8:00AM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 49.30 - 49.74
52 week 37.36 - 50.16
Open 49.32
Vol / Avg. 0.00/2.73M
Mkt cap 27.22B
P/E 5.53
Div/yield 0.13/1.05
EPS 9.00
Shares 543.92M
Beta 0.78
Inst. own 86%
Jan 31, 2017
Q4 2016 Baxter International Inc Earnings Release (Estimated)
Jan 9, 2017
Baxter International Inc at JPMorgan Healthcare Conference- Q&A Session
Jan 9, 2017
Baxter International Inc at JPMorgan Healthcare Conference
Nov 29, 2016
Baxter International Inc at Piper Jaffray Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 9.07% 48.86%
Operating margin 10.66% 7.12%
EBITD margin - 7.12%
Return on average assets - -
Return on average equity - -
Employees 50,000 -
CDP Score - 99 B


One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
.. Karp Corporate Vice President, Controller
Age: 42
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 52
Bio & Compensation  - Reuters
Robert Felicelli Corporate Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters